Supernus Pharmaceuticals, Inc. (SUPN) financial statements (2021 and earlier)

Company profile

Business Address 9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments347356140906274
Cash and cash equivalents181192100663336
Short-term investments16616440242938
Receivables8710366422617
Inventory, net of allowances, customer advances and progress billings272616171313
Inventory272616171313
Other undisclosed current assets1297354
Total current assets:473493228151106109
Noncurrent Assets
Operating lease, right-of-use asset21
Property, plant and equipment1745442
Long-term investments and receivables592419134755520
Long-term investments592419134755520
Intangible assets, net (including goodwill)2531361615
Intangible assets, net (excluding goodwill)2531361615
Deferred costs   2023 
Deferred income tax assets32
Other noncurrent assets100001
Deferred tax assets, net302142  
Total noncurrent assets:6884841961588329
TOTAL ASSETS:1,160978424310189138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities505250352934
Accounts payable1037842
Accrued liabilities373727272525
Employee-related liabilities     6
Taxes payable21216   
Interest and dividends payable     1
Debt3     
Other undisclosed current liabilities108109734527(6)
Total current liabilities:161161123815727
Noncurrent Liabilities
Long-term debt and lease obligation376329 4727
Long-term debt, excluding current maturities345329 4727
Operating lease, liability30
Liabilities, other than long-term debt911114510
Other liabilities91111444
Derivative instruments and hedges, liabilities   017
Other undisclosed noncurrent liabilities19232329311
Total noncurrent liabilities:40436334374439
Total liabilities:56552515711810166
Stockholders' equity
Stockholders' equity attributable to parent5954532671928871
Common stock000000
Additional paid in capital388370295276264230
Accumulated other comprehensive income (loss)7(3)(1)(0)(0)(0)
Retained earnings (accumulated deficit)20086(27)(84)(176)(159)
Total stockholders' equity:5954532671928871
TOTAL LIABILITIES AND EQUITY:1,160978424310189138

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues393409302215147122
Revenue, net29421014490
Cost of revenue
(Cost of Goods and Services Sold)
(17)(15)(15)(12)(8)(6)
Gross profit:376394287203139116
Operating expenses(228)(249)(187)(149)(118)(92)
Other undisclosed operating income     0
Operating income:149144100542124
Nonoperating income (expense)(1)(4)1(4)(6)(4)
Investment income, nonoperating 143213
Other nonoperating income (expense)(1)  (0)00
Interest and debt expense(18)(14)(0)(1)(2)(8)
Income from continuing operations before equity method investments, income taxes:129126100501212
Other undisclosed income from continuing operations before income taxes1814012 
Income from continuing operations before income taxes:147140101501512
Income tax expense (benefit)(34)(29)(43)41(1) 
Net income:11311157911412
Other undisclosed net income attributable to parent     8
Net income available to common stockholders, basic:11311157911420
Interest on convertible debt  0115
Dilutive securities, effect on basic earnings per share  0(0)0(4)
Net income available to common stockholders, diluted:11311157911621

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income:11311157911412
Comprehensive income:11311157911412
Other undisclosed comprehensive income (loss), net of tax, attributable to parent11(2)(1)0(0)7
Comprehensive income, net of tax, attributable to parent:12410957921420

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: